Baxter International Provides FY 2026 Earnings Guidance

The medical device company forecasts revenue and earnings for the upcoming fiscal year.

Apr. 9, 2026 at 8:21pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, industrial-looking financial machinery and equipment, conveying a sense of the complex systems and infrastructure that underpin the healthcare sector.Baxter International's FY 2026 earnings guidance reflects the complex financial machinery powering the healthcare industry.Los Angeles Today

Baxter International (NYSE:BAX) has issued its financial guidance for fiscal year 2026, providing projections for both revenue and earnings per share. The company expects to generate between $11.2 billion and $11.4 billion in revenue, compared to the current consensus estimate of $11.3 billion. Baxter also anticipates earnings per share in the range of $1.85 to $2.05, slightly above the analyst consensus of $1.93 per share.

Why it matters

Baxter's earnings guidance provides investors with an important outlook on the company's financial performance and growth prospects for the coming year. As a major player in the medical device industry, Baxter's results are closely watched as an indicator of broader trends in healthcare spending and demand.

The details

Baxter International, a global healthcare company that develops and markets medical products and therapies, updated its fiscal year 2026 guidance on Thursday. The company expects to report revenue in the range of $11.2 billion to $11.4 billion, compared to the current Wall Street consensus estimate of $11.3 billion. On the earnings side, Baxter forecast earnings per share of $1.85 to $2.05, slightly above the consensus estimate of $1.93 per share.

  • Baxter International provided the FY 2026 guidance update on Thursday, April 9, 2026.

The players

Baxter International

A global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions.

Got photos? Submit your photos here. ›

The takeaway

Baxter's earnings guidance suggests the company expects steady growth in the coming fiscal year, with revenue and profits projected to meet or exceed current analyst expectations. This outlook reflects Baxter's position as a leading provider of essential medical devices and therapies, which should continue to see demand even in a challenging economic environment.